Treatment-related differences in health related quality of life and disease specific symptoms among colon cancer survivors: Results from the population-based PROFILES registry

Verhaar, Simone; Vissers, Pauline A. J.; Maas, Huub; Poll‐Franse, Lonneke V. van de; Erning, Felice N. van; Mols, Floortje

doi:10.1016/j.ejca.2015.04.004

Cited by 26 publications

(20 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, irrespective of placing an ostomy or not, the elderly patients experience higher morbidity rates after treatment, more functional decline and more (excess) mortality compared with their young(er) counterparts [10][11][12]. Colon cancer surgery (with or without adjuvant chemotherapy) in the elderly is itself not a predictor for worse health-related QoL in the long term [39].…”

Section: Discussionmentioning

confidence: 99%

Quality of life in elderly patients with an ostomy – a study from the population‐based PROFILES registry

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Quality of life in elderly patients with an ostomy – a study from the population‐based PROFILES registry

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Colon cancer patients treated with surgery and adjuvant radio-or chemo-therapies showed no difference in health related quality of life (HRQoL) and disease-specific survival (DSS) [5]. Therefore, it is imperative to develop an effective therapeutic approach for CRC.…”

Section: Original Papermentioning

confidence: 99%

Baicalein Inhibits Proliferation Activity of Human Colorectal Cancer Cells HCT116 Through Downregulation of Ezrin

Chen

Hou

Gao

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: The present study was aimed at examining Ezrin expression in human colorectal cancer (CRC) tissues and elucidating the influence of baicalein on the proliferation of HCT116 cells. Methods: The expression of Ezrin was determined by qRT-PCR and immunohistochemistry. HCT116 cells were divided into four groups－ baicalein groups with various concentrations, pcDNA3.1-Ezrin group, si-Ezrin group and dual inhibitory group (baicalein + si-Ezrin). CCK-8 assay and flow cytometry (FCM) were employed to assess cell proliferation and to detect the distribution of cell cycle respectively. The expression levels of Ezrin protein and cell cycle-associated proteins were detected by using western blot. The proliferation ability of CRC cells was also evaluated in vivo. Results: Ezrin expression in CRC tissues was observably higher than that in adjacent colorectal tissues. With drug concentration and action time of baicalein increasing, the cell propagation capacity of HCT116 cells was decreased and the cell cycle progression was arrested. Ezrin expression was inhibited by the administration of baicalein in a dose-dependent way. The levels of CyclinD1 and CDK4 were also significantly decreased, but the expression of P53 pathway proteins P53 and P21 was markedly upregulated. Conclusion: Baicalein repressed proliferation of human colorectal cancer cells HCT116 and blocked cell cycle through downregulating Ezrin and upregulating P53 pathway-related proteins.

show abstract

“…Similarly, in the Netherlands, there were no differences on the EORTC QLQ-C30 between people aged �70 years diagnosed with CRC up to ten years earlier and an age and sex-matched normative sample. Although people aged <70 years in the CRC group had more symptoms and functioning problems than the age and sex-matched normative sample, there was no difference on global QOL [13].…”

Section: Introductionmentioning

confidence: 72%

Does quality of life return to pre-treatment levels five years after curative intent surgery for colorectal cancer? Evidence from the ColoREctal Wellbeing (CREW) study

et al. 2020

View full text Add to dashboard Cite

BackgroundThe ColoREctal Wellbeing (CREW) study is the first study to prospectively recruit colorectal cancer (CRC) patients, carry out the baseline assessment pre-treatment and follow patients up over five years to delineate the impact of treatment on health and wellbeing. MethodsCRC patients received questionnaires at baseline (pre-surgery), 3,9,15,24,36, 48 and 60 months. The primary outcome was Quality of Life in Adult Cancer Survivors (QLACS); selfefficacy, mental health, social support, affect, socio-demographics, clinical and treatment characteristics were also assessed. Representativeness was evaluated. Predictors at baseline and at 24 months of subsequent worsened quality of life (QOL) were identified using multivariable regression models. ResultsA representative cohort of 1017 non-metastatic CRC patients were recruited from 29 UK cancer centres. Around one third did not return to pre-surgery levels of QOL five years after treatment. Baseline factors associated with worsened QOL included >2 comorbidities, neoadjuvant treatment, high negative affect and low levels of self-efficacy, social support and positive affect. Predictors at 24 months included older age, low positive affect, high negative affect, fatigue and poor cognitive functioning.

show abstract

Treatment-related differences in health related quality of life and disease specific symptoms among colon cancer survivors: Results from the population-based PROFILES registry

Cited by 26 publications

References 26 publications

Quality of life in elderly patients with an ostomy – a study from the population‐based PROFILES registry

Quality of life in elderly patients with an ostomy – a study from the population‐based PROFILES registry

Baicalein Inhibits Proliferation Activity of Human Colorectal Cancer Cells HCT116 Through Downregulation of Ezrin

Does quality of life return to pre-treatment levels five years after curative intent surgery for colorectal cancer? Evidence from the ColoREctal Wellbeing (CREW) study

Contact Info

Product

Resources

About